There is a well recognized link between the bone and the immune system and in recent years there has been a major effort to elucidate the multiple functions of the molecules expressed in both bone and immune cells. Several molecules that were initially identified and studied in the immune system have been shown to have essential functions also in the bone. An interdisciplinary field embracing immune and bone biology has been brought together and called "osteoimmunology". The co-regulation of the skeletal and immune systems strikingly exemplifies the extreme complexity of such an interaction. Their interdependency must be considered in designing therapeutic approaches for either of the two systems. In other words, it is necessary to think of the osteoimmune system as a complex physiological unit. Denosumab was originally introduced to specifically target bone resorption, but it is now under evaluation for its effect on the long term immune response. Similarly, our current and still growing knowledge of the intimate link between the immune system and bone will be beneficial for the safety of drugs targeting either of these integrated systems. Given the large number of molecules exerting functions on both the skeletal and immune systems, osteoimmunological understanding is becoming increasingly important. Both bone and immune systems are frequently disrupted in cancer; and they may be crucial in regulating tumor growth and progression. Some therapies - such as bisphosphonates and receptor activator of NF-κB ligand (RANKL) targeted drugs - that aim at reducing pathologic osteolysis in cancer may interact with the immune system, thus providing potential favorable effects on survival.

Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment / Criscitiello, C; Viale, G; Gelao, L; Esposito, A; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Santangelo, Michele; Goldhirsch, A; Curigliano, G.. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 41:2(2015), pp. 61-68. [10.1016/j.ctrv.2014.12.001]

Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment.

DE LAURENTIIS, MICHELINO;DE PLACIDO, SABINO;SANTANGELO, MICHELE;
2015

Abstract

There is a well recognized link between the bone and the immune system and in recent years there has been a major effort to elucidate the multiple functions of the molecules expressed in both bone and immune cells. Several molecules that were initially identified and studied in the immune system have been shown to have essential functions also in the bone. An interdisciplinary field embracing immune and bone biology has been brought together and called "osteoimmunology". The co-regulation of the skeletal and immune systems strikingly exemplifies the extreme complexity of such an interaction. Their interdependency must be considered in designing therapeutic approaches for either of the two systems. In other words, it is necessary to think of the osteoimmune system as a complex physiological unit. Denosumab was originally introduced to specifically target bone resorption, but it is now under evaluation for its effect on the long term immune response. Similarly, our current and still growing knowledge of the intimate link between the immune system and bone will be beneficial for the safety of drugs targeting either of these integrated systems. Given the large number of molecules exerting functions on both the skeletal and immune systems, osteoimmunological understanding is becoming increasingly important. Both bone and immune systems are frequently disrupted in cancer; and they may be crucial in regulating tumor growth and progression. Some therapies - such as bisphosphonates and receptor activator of NF-κB ligand (RANKL) targeted drugs - that aim at reducing pathologic osteolysis in cancer may interact with the immune system, thus providing potential favorable effects on survival.
2015
Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment / Criscitiello, C; Viale, G; Gelao, L; Esposito, A; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Santangelo, Michele; Goldhirsch, A; Curigliano, G.. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 41:2(2015), pp. 61-68. [10.1016/j.ctrv.2014.12.001]
File in questo prodotto:
File Dimensione Formato  
2015. A. Crosstalk between Cancer Treat Rev.pdf

solo utenti autorizzati

Descrizione: articolo
Tipologia: Versione Editoriale (PDF)
Licenza: Dominio pubblico
Dimensione 775.4 kB
Formato Adobe PDF
775.4 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/595710
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 41
social impact